Issam Turk, MD
Internal Medicine · Rapid City, SDNPI 1871973420
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 62.3% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $9,128, 7.5 times the $1,210 reported in 2019. Among internal medicine clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $86.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$9K
- AbbVie$2K
- Johnson & Johnson$512
- E.r. Squibb & Sons, L.L.C.$360
- Takeda Pharmaceuticals U.S.A., Inc.$307
- Intercept Pharmaceuticals, Inc.$307
- plus $2K from 22 others
What the payments were for
- Consulting fees$7,20052%
- Travel & lodging$1,1408%
- Food & beverage$5,25538%
- Education$2422%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 10 | $8,617 |
| AbbVie | 58 | $1,759 |
| Johnson & Johnson | 13 | $512 |
| E.r. Squibb & Sons, L.L.C. | 4 | $360 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $307 |
| Intercept Pharmaceuticals, Inc. | 6 | $307 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $219 |
| Gilead | 6 | $205 |
| Merit Medical Systems Inc | 1 | $199 |
| Regeneron Healthcare Solutions, Inc. | 5 | $194 |
| Ambu Inc. | 1 | $172 |
| Ironwood Pharmaceuticals, Inc | 7 | $152 |
| Dova Pharmaceuticals | 1 | $123 |
| Boston Scientific | 1 | $122 |
| Evoke Pharma, Inc. | 1 | $115 |
| Janssen Scientific Affairs, LLC | 1 | $100 |
| Merck | 3 | $60 |
| Pfizer | 3 | $58 |
| QOL Medical, LLC | 2 | $40 |
| Ipsen Biopharmaceuticals, Inc | 1 | $34 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Ferring Pharmaceuticals Inc. | 2 | $31 |
| Ardelyx, Inc. | 2 | $27 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $19 |
| Bayer | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,836 in reported general payments places this provider in the 95th percentile of 178 internal medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 36 | $35,412 |
| LinzessLinaclotide | 59 | $35,102 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 60 | $8,344 |
| Dexlansoprazole DrDexlansoprazole | 28 | $4,933 |
| Lubiprostone | 41 | $3,254 |
| Pantoprazole Sodium | 227 | $3,038 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 99 | $1,701 |
| CholestyramineCholestyramine (With Sugar) | 25 | $1,573 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 46 | $828 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 25 | $390 |
| Amitriptyline Hcl | 28 | $334 |
| Omeprazole | 21 | $326 |
| Metoclopramide Hcl | 30 | $253 |
| Metronidazole | 11 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,759 | $70,51495 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $219 | $8,34460 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 178 internal medicine providers in South Dakota.
Other internal medicine in Rapid City
- Jennifer MayRapid City$52K
- Richard BeasleyRapid City$25K
- David EvansRapid City$3K
- Eric ChowRapid City$1K
- Matthew WerpyRapid City$873
- Kenneth HartRapid City$372
- David EatonRapid City$357
- Shailesh ThapaRapid City$238
- Marisa MedinaRapid City$228
- Nnamdi NwafoRapid City$170
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.